Breast Cancer Liquid Biopsy Market by Biomarker (Cell-free DNA, Circulating Tumor Cells, Extracellular Vesicles), End-User (Hospitals & Physician Laboratories, Reference Laboratories) - Global Forecast 2024-2030

Breast Cancer Liquid Biopsy Market by Biomarker (Cell-free DNA, Circulating Tumor Cells, Extracellular Vesicles), End-User (Hospitals & Physician Laboratories, Reference Laboratories) - Global Forecast 2024-2030


The Breast Cancer Liquid Biopsy Market size was estimated at USD 494.29 million in 2023 and expected to reach USD 589.92 million in 2024, at a CAGR 19.44% to reach USD 1,714.15 million by 2030.

Global Breast Cancer Liquid Biopsy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Breast Cancer Liquid Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Cancer Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., NeoGenomics Laboratories, Inc., Qiagen N. V. by Thermo Fisher Scientific Inc., Sysmex Corporation, and The Menarini Group.

Market Segmentation & Coverage



This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Biomarker
Cell-free DNA
Circulating Tumor Cells
Extracellular Vesicles
End-User
Hospitals & Physician Laboratories
Reference Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Breast Cancer Liquid Biopsy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Cancer Liquid Biopsy Market?
3. What are the technology trends and regulatory frameworks in the Breast Cancer Liquid Biopsy Market?
4. What is the market share of the leading vendors in the Breast Cancer Liquid Biopsy Market?
5. Which modes and strategic moves are suitable for entering the Breast Cancer Liquid Biopsy Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Breast Cancer Liquid Biopsy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of breast cancer worldwide
5.1.1.2. Increasing demand for non-invasive breast cancer treatment
5.1.1.3. Availability of funding for liquid biopsy R&D
5.1.2. Restraints
5.1.2.1. High cost of breast cancer liquid biopsy
5.1.3. Opportunities
5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
5.1.4. Challenges
5.1.4.1. Stringent regulatory issues and poor reimbursement policies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Breast Cancer Liquid Biopsy Market, by Biomarker
6.1. Introduction
6.2. Cell-free DNA
6.3. Circulating Tumor Cells
6.4. Extracellular Vesicles
7. Breast Cancer Liquid Biopsy Market, by End-User
7.1. Introduction
7.2. Hospitals & Physician Laboratories
7.3. Reference Laboratories
8. Americas Breast Cancer Liquid Biopsy Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Breast Cancer Liquid Biopsy Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Adaptive Biotechnologies Corporation
12.1.2. Bio-Rad Laboratories, Inc.
12.1.3. Biocept, Inc.
12.1.4. Biodesix, Inc.
12.1.5. Epic Sciences Inc.
12.1.6. Exact Sciences Corporation
12.1.7. F. Hoffmann-La Roche Ltd.
12.1.8. Fluxion Biosciences Inc.
12.1.9. Guardant Health, Inc.
12.1.10. Illumina, Inc.
12.1.11. Johnson & Johnson Services, Inc.
12.1.12. NeoGenomics Laboratories, Inc.
12.1.13. Qiagen N. V. by Thermo Fisher Scientific Inc.
12.1.14. Sysmex Corporation
12.1.15. The Menarini Group
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
FIGURE 3. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
FIGURE 7. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2030 (%)
FIGURE 8. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings